Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Daniel P. Petrylak; Catherine M. Tangen; Maha Hussain; Primo N. Lara; Jeffrey A. Jones; Mary Ellen Taplin; Patrick A. Burch; Donna L. Berry; Carol M. Moinpour; Manish Kohli; Mitchell C. Benson; Eric J. Small; Derek Raghavan; E. David Crawford

doi:10.1056/nejmoa041318

Abstract

The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.

Keywords

DocetaxelEstramustineMitoxantroneMedicinePrednisoneProstate cancerInternal medicineUrologyHazard ratioChemotherapyVinblastineOncologyCancerConfidence interval

Affiliated Institutions

Related Publications

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis , Andrew Martin , Martin R. Stockler +29 more

Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receivin...

2019 New England Journal of Medicine 1481 citations

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima , Manish A. Shah , Kei Muro +24 more

PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phas...

2020 Journal of Clinical Oncology 1110 citations

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Kim N. , Neeraj Agarwal , Anders Bjartell +17 more

In this trial involving patients with metastatic, castration-sensitive prostate cancer, overall survival and radiographic progression-free survival were significantly longer wit...

2019 New England Journal of Medicine 1384 citations

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Shirish M. Gadgeel , Delvys Rodríguez‐Abreu , Giovanna Speranza +23 more

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo ...

2020 Journal of Clinical Oncology 1095 citations

Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial

Philip Bonomi , KyungMann Kim , Diane L. Fairclough +5 more

PURPOSE: Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non–small-cell lung cancer (NSCLC). To determine...

2000 Journal of Clinical Oncology 593 citations

Publication Info

Year: 2004
Type: article
Volume: 351
Issue: 15
Pages: 1513-1520
Citations: 3663
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3663

OpenAlex

Cite This

APA Style

                            
                                
                                    Daniel P. Petrylak, 
                                
                                    Catherine M. Tangen, 
                                
                                    Maha Hussain
                                
                                et al.
                            
                            (2004). 
                            Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. 
                            New England Journal of Medicine
                            , 351
                            (15)
                            , 1513-1520.
                            https://doi.org/10.1056/nejmoa041318
                        

Identifiers

DOI: 10.1056/nejmoa041318